Last updated: 2026-09-07 01:28:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
BioMarin Pharmaceuticals Inc. (BMRN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $66,53, with a market capitalization of $12,88B and a P/E ratio of 176,48. Over the past 52 weeks, its price has ranged from $49,26 to $70,98. This page covers its latest market performance, valuation, price trends and company information.
$12,88B | |
$65,79 | |
$151,75 | |
$3,87 | |
$66,43 | |
886,72K | |
1,98M | |
176,48 | |
$70,98 | |
$49,26 | |
-- | |
-- |
BioMarin Pharmaceuticals Inc. (BMRN) last closed at $66,43 as of 2026-09-04 23:31:00, unchanged from the previous close of $66,43.
During the latest regular trading session, BMRN traded between $3,87 and $151,75, with a volume of 886,72K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, BioMarin Pharmaceuticals Inc. (BMRN) moved from $65,29 to $66,53, representing a gain of 1,90% ($1,24).
The stock traded between $64,07 and $67,70 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 1,82 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 79,5%
BMRN is currently trading at $66,53, placing it 79,5% of the way from its 52-week low of $49,26 to its 52-week high of $70,98. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 3221 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BioMarin Pharmaceuticals Inc. (BMRN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.